AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18810506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5′-triphosphate (ATP) infusions, maximum of eight weekly intravenous 8-10 h infusions
Number of subjects: 51
Study 16407509 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol cyclosporine (300 mg, three days a week for two years)
Number of subjects: 58
Study 16407509 — intervention group
Group type: COMPARATOR
Intervention: Aerosol placebo
Number of subjects: 58
Study 16407509 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol cyclosporine
Number of subjects: 58
Study 12823382 — intervention group
Group type: EXPERIMENTAL
Intervention: Infra-diaphragmatic irradiation
Number of subjects: 487
Study 12823382 — intervention group
Group type: EXPERIMENTAL
Intervention: Infra- and supra-diaphragmatic irradiation
Number of subjects: 487
Study 12823382 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 487
Study 10789574 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% glutaraldehyde
Number of subjects: 40
Study 10789574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylene oxide
Number of subjects: 40
Study 9200379 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 436
Study 9200379 — intervention group
Group type: COMPARATOR
Intervention: Seroreverters (uninfected infants of HIV-1-infected mothers)
Number of subjects: 436
Study 9200379 — intervention group
Group type: COMPARATOR
Intervention: Seronegative infants (uninfected infants born to HIV-negative mothers)
Number of subjects: 436
Study 8307542 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrazepam (150 mg or a lower dose from the third day onward)
Number of subjects: 20
Study 8307542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8307542 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrazepam
Number of subjects: 20
Study 3327362 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (up to 120 micrograms kg‐1 min‐1) after saline
Number of subjects: 6
Study 3327362 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine after propranolol (0.2 mg kg‐1 body weight)
Number of subjects: 6
Study 3327362 — intervention group
Group type: COMPARATOR
Intervention: Propranolol plus atropine (0.2 mg kg‐1 plus 0.04 mg kg‐1)
Number of subjects: 6
Study 3327362 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine compared with saline on standing
Number of subjects: 6
Study 3327362 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine during Valsalva manoeuvre
Number of subjects: 6
Study 30957838 — intervention group
Group type: EXPERIMENTAL
Intervention: TeraPCA software for Principal Component Analysis
Number of subjects: 1000000
Study 30957838 — intervention group
Group type: COMPARATOR
Intervention: Current state-of-the-art software for Principal Component Analysis
Number of subjects: 1000000
Study 28062271 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Number of subjects: 94
Study 28062271 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Goals
Number of subjects: 94
Study 28062271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined
Number of subjects: 94
Study 28062271 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study 26163311 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music during surgical closure
Number of subjects: 0
Study 24319955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegasys (pegylated interferon alpha‐2a) for 48 weeks
Number of subjects: 107
Study 24319955 — intervention group
Group type: COMPARATOR
Intervention: Control group (ALT > 2 x ULN)
Number of subjects: 107
Study 24319955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study 21226787 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical screening + access to a website and coaching
Number of subjects: 287
Study 21226787 — intervention group
Group type: COMPARATOR
Intervention: Usual care (medical screening only)
Number of subjects: 287
Study 17697788 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual fluency based on speed of processing
Number of subjects: 0
Study 17697788 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective experience of fluency
Number of subjects: 0
Study 16517329 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of 3% chloroprocaine
Number of subjects: 40
Study 16517329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 13129737 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan therapy
Number of subjects: 45
Study 13129737 — intervention group
Group type: COMPARATOR
Intervention: No losartan therapy (Control)
Number of subjects: 45
Study 11204662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (Eloxatin) in preoperative combined‐modality treatment
Number of subjects: 0
Study 11204662 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with radiation and fluorouracil (5‐FU)‐based chemotherapy
Number of subjects: 0
Study 8869673 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (1.3 MAC)
Number of subjects: 41
Study 8869673 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1.3 MAC)
Number of subjects: 41
Study 8869673 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane and Isoflurane (both groups)
Number of subjects: 41
Study 1497152 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation of radiographs of both the injured and uninjured elbow
Number of subjects: 25
Study 1497152 — intervention group
Group type: COMPARATOR
Intervention: Interpretation of radiographs of the injured elbow only
Number of subjects: 25
Study 6475561 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol 350 mg I/ml (Omnipaque)
Number of subjects: 30
Study 6475561 — intervention group
Group type: COMPARATOR
Intervention: Meglumine, Na‐Ca‐metrizoate 370 mg I/ml (Isopaque Coronar)
Number of subjects: 30
Study 30468530 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose UVA1 (130 J/cm2)
Number of subjects: 27
Study 30468530 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose UVA1 (60 J/cm2)
Number of subjects: 27
Study 29424239 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (lixisenatide, liraglutide, semaglutide, exenatide)
Number of subjects: 4
Study 29424239 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (liraglutide)
Number of subjects: 4
Study 29424239 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (semaglutide)
Number of subjects: 4
Study 29424239 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (exenatide)
Number of subjects: 4
Study 29424239 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 receptor agonists
Number of subjects: 4
Study 26224021 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF)
Number of subjects: 0
Study 26224021 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF) with maternity vouchers
Number of subjects: 0
Study 26224021 — intervention group
Group type: EXPERIMENTAL
Intervention: PBF with management authority within a health district
Number of subjects: 0
Study 24470641 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop automatic control (CLAC)
Number of subjects: 34
Study 24470641 — intervention group
Group type: COMPARATOR
Intervention: Routine manual control (RMC)
Number of subjects: 34
Study 22717961 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (PDS plus®)
Number of subjects: 485
Study 22717961 — intervention group
Group type: COMPARATOR
Intervention: Uncoated sutures (PDS II®)
Number of subjects: 485
Study 19631869 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Aneurysm Repair (AAR)
Number of subjects: 52
Study 19631869 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Revascularization (CR)
Number of subjects: 52
Study 19631869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Extremity Revascularization (LER)
Number of subjects: 52
Study 17440207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate number of linguistic cues in analogies
Number of subjects: 0
Study 17440207 — intervention group
Group type: COMPARATOR
Intervention: High cue frequency versions of analogies
Number of subjects: 0
Study 17440207 — intervention group
Group type: COMPARATOR
Intervention: Low cue frequency versions of analogies
Number of subjects: 0
Study 15077083 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI for AMI
Number of subjects: 695
Study 15077083 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent ST-segment resolution (STR) after PCI
Number of subjects: 695
Study 15077083 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 695
Study 12530280 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (single oral dose)
Number of subjects: 98
Study 12530280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 9800052 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg) once daily
Number of subjects: 132
Study 9800052 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem CR (90-120 mg) twice daily
Number of subjects: 132
Study 9800052 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 132
Study 9800052 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 132
Study 9800052 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem CR
Number of subjects: 132
Study 8818853 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg once daily for 3 days)
Number of subjects: 200
Study 8818853 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (20 mg/kg/day in three divided doses for 10 days)
Number of subjects: 200
Study 2137666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isradipine administered once daily
Number of subjects: 76
Study 2137666 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release isradipine administered twice daily
Number of subjects: 76
Study 2137666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isradipine
Number of subjects: 76
Study 7022879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antithymocyte globulin (ATG) therapy
Number of subjects: 130
Study 7022879 — intervention group
Group type: COMPARATOR
Intervention: Standard antirejection treatment (SAT) of steroid pulsing and local irradiation
Number of subjects: 130
Study 7022879 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results for patient survival
Number of subjects: 130
Study 31651529 — intervention group
Group type: EXPERIMENTAL
Intervention: R-dihydroetorphine 12.5 ng/kg
Number of subjects: 20
Study 31651529 — intervention group
Group type: EXPERIMENTAL
Intervention: R-dihydroetorphine 75 ng/kg
Number of subjects: 20
Study 31651529 — intervention group
Group type: EXPERIMENTAL
Intervention: R-dihydroetorphine 125 ng/kg
Number of subjects: 20
Study 31651529 — intervention group
Group type: EXPERIMENTAL
Intervention: R-dihydroetorphine 150 ng/kg
Number of subjects: 20
Study 31651529 — intervention group
Group type: EXPERIMENTAL
Intervention: R-dihydroetorphine
Number of subjects: 20
Study 28296744 — intervention group
Group type: EXPERIMENTAL
Intervention: CoTOL
Number of subjects: 210
Study 28296744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 25546369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution fasting (50mg)
Number of subjects: 36
Study 25546369 — intervention group
Group type: COMPARATOR
Intervention: Tablet fasting (50mg)
Number of subjects: 36
Study 25546369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution fed (50mg)
Number of subjects: 36
Study 25546369 — intervention group
Group type: COMPARATOR
Intervention: Tablet fed (50mg)
Number of subjects: 36
Study 24918481 — intervention group
Group type: EXPERIMENTAL
Intervention: Active suction (AS group)
Number of subjects: 75
Study 24918481 — intervention group
Group type: COMPARATOR
Intervention: Natural evacuation (NE group)
Number of subjects: 75
Study 22155024 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA) methods for acute pain management
Number of subjects: 38
Study 22155024 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including referrals from urgent care and SCD clinics
Number of subjects: 38
Study 22155024 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of site-specific factors and policies
Number of subjects: 38
Study 21156060 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention of community mobilization, birth attendant training, and improvement of quality of care in health facilities
Number of subjects: 106
Study 21156060 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 106
Study 18054724 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n=15)
Number of subjects: 47
Study 18054724 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (n=16)
Number of subjects: 47
Study 18054724 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupressure (n=16)
Number of subjects: 47
Study 16267767 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment (early treatment group, n=64)
Number of subjects: 287
Study 16267767 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (n=66)
Number of subjects: 287
Study 16267767 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment (n=105)
Number of subjects: 287
Study 16267767 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (n=122)
Number of subjects: 287
Study 11925631 — intervention group
Group type: EXPERIMENTAL
Intervention: Free diet group (Group 2)
Number of subjects: 30
Study 11925631 — intervention group
Group type: COMPARATOR
Intervention: Standard diet group (Group 1)
Number of subjects: 30
Study 11925631 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of bile reflux with intragastric pH
Number of subjects: 30
Study 11925631 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 30
Study 10446081 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 265
Study 10446081 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil therapy
Number of subjects: 265
Study 10446081 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 265
Study 8543715 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR treatment (3 sessions of 90 minutes each)
Number of subjects: 80
Study 8543715 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment condition
Number of subjects: 80
Study 2102432 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Ibuprofen administered directly postoperatively (2nd administration after 6 hours)
Number of subjects: 0
Study 2102432 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen taken as required
Number of subjects: 0
Study 28134 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorazepate
Number of subjects: 0
Study 28134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31707849 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 14298
Study 31707849 — intervention group
Group type: COMPARATOR
Intervention: Control (no evolocumab)
Number of subjects: 14298
Study 31072848 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive catheter ablation (CA) at the time of ICD implantation
Number of subjects: 208
Study 31072848 — intervention group
Group type: COMPARATOR
Intervention: Deferred catheter ablation (CA) after the third appropriate ICD shock for ventricular tachycardia
Number of subjects: 208
Study 27390153 — intervention group
Group type: EXPERIMENTAL
Intervention: Early provision of ankle-foot orthosis (Week 1)
Number of subjects: 33
Study 27390153 — intervention group
Group type: COMPARATOR
Intervention: Delayed provision of ankle-foot orthosis (Week 9)
Number of subjects: 33
Study 27390153 — intervention group
Group type: EXPERIMENTAL
Intervention: Early provision of ankle-foot orthosis
Number of subjects: 33
Study 25833980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) 20 g/d
Number of subjects: 1057
Study 25833980 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA)
Number of subjects: 1057
Study 25833980 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrient (MMN)
Number of subjects: 1057
Study 21946544 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma group with ET-1 level of 3.27±1.25 pg/mL
Number of subjects: 102
Study 21946544 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal tension glaucoma group with ET-1 level of 3.12±1.46 pg/mL
Number of subjects: 102
Study 21946544 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angle-closure glaucoma group with ET-1 level of 2.58±0.22 pg/mL
Number of subjects: 102
Study 21946544 — intervention group
Group type: COMPARATOR
Intervention: Control group with ET-1 level of 1.53±1.49 pg/mL
Number of subjects: 102
Study 22315765 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg kg(‐1)
Number of subjects: 90
Study 22315765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 6 mg kg(‐1)
Number of subjects: 90
Study 22315765 — intervention group
Group type: COMPARATOR
Intervention: Combination of ketamine 2.5 mg kg(‐1) and midazolam 0.25 mg kg(‐1)
Number of subjects: 90
Study 19700035 — intervention group
Group type: EXPERIMENTAL
Intervention: Chapatis containing 4 g beta-glucan
Number of subjects: 8
Study 19700035 — intervention group
Group type: EXPERIMENTAL
Intervention: Chapatis containing 8 g beta-glucan
Number of subjects: 8
Study 19700035 — intervention group
Group type: COMPARATOR
Intervention: Chapatis containing 2 g beta-glucan
Number of subjects: 8
Study 19700035 — intervention group
Group type: COMPARATOR
Intervention: Chapatis containing 6 g beta-glucan
Number of subjects: 8
Study 19700035 — intervention group
Group type: COMPARATOR
Intervention: Control chapatis (0 g beta-glucan)
Number of subjects: 8
Study 17122236 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Shot Spinal (SSS) with 2 mL of 0.5% hyperbaric bupivacaine
Number of subjects: 40
Study 17122236 — intervention group
Group type: COMPARATOR
Intervention: Combined Spinal Epidural (CSE) with equivalent dose of hyperbaric bupivacaine
Number of subjects: 40
Study 14709426 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-learning model (experimental group)
Number of subjects: 150
Study 14709426 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based teaching methods (control group)
Number of subjects: 150
Study 14709426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups rated self-proficiency
Number of subjects: 150
Study 14709426 — intervention group
Group type: COMPARATOR
Intervention: Instructor ratings of student proficiency
Number of subjects: 150
Study 11930834 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 35
Study 11930834 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) combined with cyclophosphamide (CPH)
Number of subjects: 35
Study 11930834 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 35
Study 9632030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20-60 mg plus group psychotherapy
Number of subjects: 47
Study 9632030 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus group psychotherapy
Number of subjects: 47
Study 9727573 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV-3TC (200 mg three times daily and 150 mg twice daily)
Number of subjects: 47
Study 9727573 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T-3TC (40 mg and 150 mg, both twice daily)
Number of subjects: 47
Study 9727573 — intervention group
Group type: COMPARATOR
Intervention: Indinavir added to both groups if plasma HIV RNA level at week 8 or thereafter was > 500 copies/ml
Number of subjects: 47
Study 2495147 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-TPN (50% BCAA)
Number of subjects: 9
Study 15907 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocoagulation
Number of subjects: 299
Study 15907 — intervention group
Group type: COMPARATOR
Intervention: Tubal rings
Number of subjects: 299
Study 30958388 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous cannabis use
Number of subjects: 78
Study 30958388 — intervention group
Group type: COMPARATOR
Intervention: Nonhazardous cannabis use
Number of subjects: 78
Study 30958388 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of cannabis
Number of subjects: 78
Study 30958388 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater cannabis use severity
Number of subjects: 78
Study 27388251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.1%
Number of subjects: 175
Study 27388251 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 175
Study 26123989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine supplementation (10 g/day for 3 or 6 months)
Number of subjects: 0
Study 26123989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-arginine (0.5 g Arg/kg bodyweight for 30 min)
Number of subjects: 0
Study 26123989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23616509 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (rich in daidzein, 60%) providing 94 mg isoflavones daily for 8 weeks
Number of subjects: 30
Study 23616509 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 30
Study 19909291 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Vitrectomy (PV)
Number of subjects: 0
Study 19909291 — intervention group
Group type: COMPARATOR
Intervention: Scleral Buckling (SB)
Number of subjects: 0
Study 19838433 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stented group (n=55)
Number of subjects: 110
Study 19838433 — intervention group
Group type: COMPARATOR
Intervention: Stented group (n=55)
Number of subjects: 110
Study 16960472 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg/d
Number of subjects: 50
Study 16960472 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptans
Number of subjects: 50
Study 16960472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 14716835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination
Number of subjects: 31